Dengue vaccine clinical trials in India - An opportunity to inform the global response to a re-emerging disease challenge

被引：2

作者：

Fauci, Anthony ^{[1
]}

Erbelding, Emily ^{[2
]}

Whitehead, Stephen ^{[3
]}

Cassetti, M. Cristina ^{[4
]}

Handley, F. Gray ^{[5
]}

Gupta, Ranjan ^{[6
]}

机构：

[1] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[2] NIAID, Div Microbiol & Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[3] NIAID, Lab Infect Dis, NIH, Bethesda, MD 20892 USA

[4] NIAID, Virol Branch, Div Microbiol & Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[5] NIAID, Off Director, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[6] NIAID, Off Global Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2019年 / 84卷

关键词：

PATHOGENESIS; ENHANCEMENT; FEVER;

D O I：

10.1016/j.ijid.2019.03.016

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：S4 / S6

页数：3

共 33 条

[31] Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen
Monath, TP
Guirakhoo, F
Nichols, R
Yoksan, S
Schrader, R
Murphy, C
Blum, P
Woodward, S
McCarthy, K
Mathis, D
Johnson, C
Bedford, P
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (08): : 1213 - 1230
[32] Letter to the Editor in response to "N Folschweiller, V Berlaimont, SR Skinner, CM Wheeler, N Karkada, F Struyf, M Ryser. Letter to the Editor in response to OM Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemp. Clin. Trials (2016), doi: 10.1016/j.cct.2016.12.022"
Bautista, Oliver M.
Luxembourg, Alain
CONTEMPORARY CLINICAL TRIALS, 2017, 54 : 105 - 105
[33] COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al
Gianfrancesco, Milena
Hyrich, Kimme L.
Yazdany, Jinoos
Machado, Pedro M.
Robinson, Philip C.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (10)

← 1 2 3 4 →